Holen Sie sich die Stockscreener-App
5.66
2.92%
-0.17
Handel nachbörslich:
5.38
-0.28
-4.95%
Schlusskurs vom Vortag:
$5.83
Offen:
$5.8
24-Stunden-Volumen:
491.59K
Relative Volume:
1.08
Marktkapitalisierung:
$348.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-2.5268
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
+8.22%
1M Leistung:
+22.25%
6M Leistung:
+2.35%
1J Leistung:
+29.22%
1-Tages-Spanne:
$5.4529
$5.875
1-Wochen-Bereich:
$5.29
$6.25
52-Wochen-Spanne:
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
5.66 | 321.70M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
What drives Monte Rosa Therapeutics Inc. stock priceExplosive trading opportunities - jammulinksnews.com
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
What analysts say about Monte Rosa Therapeutics Inc. stockExplosive returns - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewswire
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Market Movement, Down and Up - investchronicle.com
How Monte Rosa Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - beatles.ru
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Consultation - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention2x 3x 5x Pick Alert - Newser
With surface mimicry, molecular glues shed hairpin need - BioWorld MedTech
Monte Rosa Therapeutics (GLUE) Soars 4.55% on Clinical Trial Progress - AInvest
Monte Rosa Therapeutics (GLUE): Pioneering the Future of Drug Discovery with Molecular Glue Degraders - AInvest
Monte Rosa Therapeutics Announces Publication of Landmark Research on Molecular Glue Degraders in Science - Nasdaq
Monte Rosa Announces Publication in Science of Key Insights - GlobeNewswire
Monte Rosa Announces Publication in Science of Key Insights That Enable Next Generation Molecular Glue Degrader Medicines - MarketScreener
Monte Rosa's AI Discovery Unlocks 100+ New Drug Targets, Featured in Science Magazine Cover Story - Stock Titan
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Monte Rosa advances novel inflammatory disease treatment By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 - MarketScreener
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):